Medtronic PLC (MDT)

NYSE
Currency in USD
88.49
+0.43(+0.49%)
Closed·
Pre Market
87.03-1.46(-1.65%)
·
MDT Scorecard
Full Analysis
Management has been aggressively buying back shares
MDT is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
87.6588.53
52 wk Range
75.9696.25
Key Statistics
Edit
Prev. Close
88.49
Open
88.03
Day's Range
87.65-88.53
52 wk Range
75.96-96.25
Volume
5.86M
Average Volume (3m)
7.95M
1-Year Change
7.61%
Book Value / Share
37.44
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
MDT Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
95.43
Upside
+7.84%
Members' Sentiments
Bearish
Bullish
ProTips
Has raised its dividend for 11 consecutive years

Medtronic PLC News & Analysis

Show more

Medtronic PLC Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists; and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat other non-exclusive diseases and conditions; and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems, and InPen, a smart insulin pen system. The company was founded in 1949 and is headquartered in Galway, Ireland.

Medtronic PLC SWOT Analysis


Financial Resilience
Medtronic maintains a robust "GOOD" financial health score, with year-to-date returns of 14.56% and a market cap of $117.4 billion, showcasing its market strength
Innovation Pipeline
Explore Medtronic's growth drivers, including Cardiac Ablation Solutions, renal denervation, and the Hugo surgical robot, poised to reshape medical technology markets
Market Dynamics
Delve into Medtronic's competitive landscape, analyzing its diversified portfolio and strategies to maintain leadership amid intense industry rivalry
Analyst Outlook
Analyst price targets range from $104 to $109, with expectations of accelerating EPS growth and potential for margin expansion driving positive sentiment
Read full SWOT analysis

Medtronic PLC Earnings Call Summary for Q1/2025

  • Q1 FY2025: Revenue up 5.3%, adjusted EPS up 3% (8% constant currency). Full-year guidance raised to 4.5-5% organic revenue growth.
  • Key growth drivers: Cardiac Rhythm Management, Micro leadless pacemaker. Surgical segment growth moderate due to market factors.
  • Global partnership with Abbott for integrated CGM solutions. Gary Corona appointed Interim CFO, succeeding Karen Parkhill.
  • Focus on tuck-in M&A, share repurchases. Expects improved operating margins in H2. Committed to Hugo surgical robot as midterm growth driver.
  • Optimistic about pulsed field ablation and renal denervation growth. Q2 earnings call scheduled for November 19.
Last Updated: 08/21/2024, 05:50 AM
Read Full Transcript

Compare MDT to Peers and Sector

Metrics to compare
MDT
Peers
Sector
Relationship
P/E Ratio
24.3x−2.3x−0.5x
PEG Ratio
0.79−0.100.00
Price/Book
2.4x2.1x2.6x
Price / LTM Sales
3.4x2.5x3.1x
Upside (Analyst Target)
7.9%20.1%48.3%
Fair Value Upside
Unlock23.0%7.6%Unlock

Analyst Ratings

17 Buy
13 Hold
2 Sell
Ratings:
32 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 95.43
(+7.84% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 3.63%
Dividend Yield
3.23%
Industry Median 0.75%
Annualized payout
2.84
Paid quarterly
5-Years Growth
+5.33%
Growth Streak

Earnings

Latest Release
May 21, 2025
EPS / Forecast
1.62 / 1.58
Revenue / Forecast
8.93B / 8.82B
EPS Revisions
Last 90 days

MDT Income Statement

People Also Watch

505.87
SPGI
-1.58%
192.42
ABBV
+0.48%
309.75
ADP
-0.84%
156.66
JNJ
+0.90%

FAQ

What Is the Medtronic (MDT) Stock Price Today?

The Medtronic stock price today is 88.49

What Stock Exchange Does Medtronic Trade On?

Medtronic is listed and trades on the New York Stock Exchange stock exchange.

What Is the Stock Symbol for Medtronic?

The stock symbol for Medtronic is "MDT."

Does Medtronic Pay Dividends? What’s The Current Dividend Yield?

The Medtronic dividend yield is 3.21%.

What Is the Medtronic Market Cap?

As of today, Medtronic market cap is 113.44B.

What Is Medtronic's Earnings Per Share (TTM)?

The Medtronic EPS (TTM) is 3.63.

When Is the Next Medtronic Earnings Date?

Medtronic will release its next earnings report on Aug 18, 2025.

From a Technical Analysis Perspective, Is MDT a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Medtronic Stock Split?

Medtronic has split 8 times.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.